#Podcast #ASCO2025 #TOPpulmón #ScienceLink Chicago 2025: lo mejor en cáncer de pulmón Dr. Jorge A. Alatorre (Jorge Alatorre Alexander) y Dr. Santiago Viteri (Santiago Viteri) buff.ly/UdDPnwu

ALAT 2025: the leading respiratory congress in Latin America. Honored to collaborate with pulmonologists, thoracic surgeons, pathologists, and multidisciplinary teams to build bridges across the region in lung cancer care. #ALAT Respira-INER SMNyCT IASLC

Empatía que cambia al mundo… Niña mostrando a sus amigos en la escuela su nueva pierna protésica.♥️😊

On this day, patients with #HER2+ #lungcancer got access to the first oral targeted therapy for HER2+ disease. -#zongertinib ➡️Beamion trial 1L: ORR was 75% with 58% having a DOR ≥ 6 mos. ➡️previously treated with HER2-targeted ADC, ORR was 44% with 27% having a DOR ≥ 6 months.

#OncoTime #ScienceLink #Amivantamab Dr. Jorge Alatorre (Jorge Alatorre Alexander) y Dr. Manuel Cobo buff.ly/ekwTado

Major milestone in Mexico’s fight vs lung cancer: INER integrates AI to boost early detection through DETECAP & Nodule Clinic. Grateful to INER leadership & AstraZeneca for driving innovation. Next step: strong primary care networks. #LungCancer #AI #AstraZeneca

#ScienceLink #Podcast Dr. Jorge Alatorre (Jorge Alatorre Alexander ), Dra. Narjust Florez (Narjust Florez, MD, FASCO ) y Dr. Sergio Mejía buff.ly/xmK7Khv

Flaura 2 trial. OS Benef of comb ( osi + chemo)47.5 vs 37.6 of osi. Ew/ HR 0.7. Not all patients continued pen ( option to te challenge w/ pem+ plat in 2 nd Line?). WCLC IASLC congrats d.planchard

EGFRm treat, is evolving very fast. In Mexico we have 34% of Adenoca pts facing this dis. It was a pleasure to participate in Mariposa Trial, a combination w/o chemo. Trying to do things better for them, w/ great results for OS just published in NEJM WCLC IASLC

Harmoni! Amazing MoCl Ab! Ivonescimab has demonstrated in EGFRm global popullation to be effective & correlates w/Harmoni A results. IASLC WCLC !

WCLC 2025! With great Mexican friends !!

Amazing Spanish #WCLC25 highlights episode coming soon… With Laura Mezquita and Jorge Alatorre Alexander -FLAURA-2 OS -ARROS-1 trial -ALCHEMIST - ALK/Crizotinib arm Stay tuned

We must stop thinking that response to immunotherapy is only about PD-L1. The quality of the neoantigen, its affinity to the TCR, and other molecular factors are fundamental.

Amazing Congress of Peruvian Society of Cancer in Lima! Also great chance to see friends like Jose Luis Elias, Lenny Bravo y Jenny of the Peruvian university Universidad Privada San Juan Bautista !!

⸻ Honored to share updates on advances in EGFR-mutated advanced lung adenocarcinoma at the Peruvian Cancer Society Congress, and to interact with students at Universidad Privada San Juan Bautista. Universidad Privada San Juan Bautista

A milestone for respiratory health in Mexico 🇲🇽 At INER, we’ve started implementing artificial intelligence tool for chest imaging that enhances early detection of lung diseases — including lung cancer, the leading cause of cancer death worldwide. AstraZeneca Secretaría de Salud Pública de la Ciudad de México qureAI

Stage III is getting more interesting & probably the future will depend on response (and restaging). Amazing discussion Martin Reck! Is this a neoadj or a conversion strategy!! Thanks Lizza & Noemi

Very elegant discussion on exon 20 options by d.planchard at #ESMO25

Ivonescimab + chemo in Harmoni-6 in Sq LC ( PFS HR 0.6) is concordant w/ prev results presented previously in LC ( Harm 2 & Harm-A). It benefit all subgroups regardless of PD-L1 status. Congrat for the authors!! #ESMO25

In EGFRm post osi, 2nd liner sac-TMT showed 8.3 vs 4.3 in Chemo arm. All subgroups showed benefit. ORR 60%. More stomatitis. Great results ! Published NEJM #ESMO25 congrat to the authors!!